Cervical Cancer Drugs Market Research Report Analysis and Forecasts to 2026

Cervical cancer develops in women’s cervix, and mainly affects sexually active women aged between 30 and 45. Cervical cancer often shows no symptoms in early stages. However, the death rate of cervical cancer can be significantly reduced with use of Pap test (Papanicolaou test): a screening procedure which can detect the changes in the cervix before the cancer develops. There are different types of cervical cancer, out of which two main types are squamous cell cancer and adenocarcinoma.

Download PDF Brochure Of This Research Report @ www.coherentmarketinsights.com/insight/request-pdf/1746

Cervical Cancer Drugs Market Drivers:

Increasing number of drug approval done by U.S. Food and Drug Administration (FDA) for the treatment of cervical cancer is expected to drive growth of the cervical cancer drugs market over the forecast period. For instance, in September 2017, U.S. Food and Drug Administration (FDA) approved Mvasi (bevacizumab-awwb) as a biosimilar to Avastin (bevacizumab) for the treatment of multiple types of cancer, which includes cervical, lung, brain, colorectal and kidney cancer. Mvasi is indicated for use in persistent, recurrent, or metastatic cervical cancer. In August 2014, U.S. FDA approved Genentech’s Avastin, which is bevacizumab solution for intravenous infusion in combination with paclitaxel for the treatment of persistent, recurrent, or metastatic cervical cancer.

Increasing funding for cancer research, rising insurance coverage, and increase in the number of new targeted cancer drugs are expected to support the revenue growth of cervical cancer drugs market. For instance, National Cancer Institute, in 2015, spent around US$ 4,480 million on cancer research, which include cervical cancer, lung cancer, colorectal cancer, liver cancer, breast cancer, leukaemia, ovarian cancer, and uterine cancer. Furthermore, according to the American Cancer Society, U.S. invested around US$ 87.8 billion in 2014 on cancer research, in which the major cost accounting for around 44%, was paid by private insurance companies.

Cervical Cancer Drugs Market - Regional Analysis:

Geographically, cervical cancer drugs market is segmented into North America, Latin America, Europe, Middle East, Asia Pacific, and Africa. North America holds dominant position in cervical cancer drugs market, owing to increasing incidences of cervical cancer and growing research and development activities by various healthcare regulatory organizations in these region. For instance, according to the American Cancer Society’s (ACS) estimates for cervical cancer in the U.S. for 2018, around 13, 240 new cases of invasive cervical cancer were diagnosed and around 4,170 women are expected to die from cervical cancer. For instance, in 2013, Cervical Cancer-Free Coalition (CCFC) announced a collaborative research projects with funds ranging from US$ 5,000-US $10,000 each, which are focused on cervical cancer treatment in the U.S. 

Cervical Cancer Drugs Market Competitive Landscape:

Some of the key players operating in the cervical cancer drugs market include F. Hoffmann-La Roche Ltd., Hetero, GlaxoSmithKline, plc, Eli Lilly and Company, Alnylam Pharmaceuticals, Inc., Pfizer, Inc., AstraZeneca plc, Allergan plc, Biocon Limited, Bristol-Myers Squibb Company, and Novartis AG. Key players operating in the market are focused on organic growth strategies, in order to enhance its market share and retain its competence in the market. For instance, in July 2014, MedImmune: a biologics research and development division of AstraZeneca entered into a clinical trial collaboration with Advaxis. According to the agreement, both companies conducted Phase I/II immunotherapy study to evaluate the safety and efficacy of MedImmune’s investigational anti-PD-L1 immune checkpoint inhibitor: MEDI4736, in combination with Advaxis’ cancer immunotherapy vaccine: ADXS-HPV. These study is conducted to develop treatment for patients with advanced, recurrent or refractory Human Papillomavirus (HPV)-associated cervical cancer.

For More Information @ https://www.coherentmarketinsights.com/ongoing-insight/cervical-cancer-drugs-market-1746

Cervical Cancer Drugs Market Taxonomy:

By Cancer Type:
• Squamous Cell Cancer
• Adenocarcinoma

By Drug Type:
- By Prevention
◦ Cervarix
◦ Gardasil 9
◦ Recombinant Human Papillomavirus (HPV) Bivalent Vaccine
◦ Recombinant Human Papillomavirus (HPV) Nonavalent Vaccine
◦ Recombinant Human Papillomavirus (HPV) Quadrivalent Vaccine
◦ Others

- By Treatment
◦ Avastin (Bevacizumab)
◦ Bevacizumab
◦ Bleomycin
◦ Blenoxane (Bleomycin)
◦ Others

By Distribution Channels:
• Hospitals Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Geography:
• North America
• Latin America
• Europe
• Asia Pacific
• Middle East
• Africa

Request For Customization @ https://www.coherentmarketinsights.com/insight/request-customization/1746

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us: 

Mr. Shah
Coherent Market Insights
1001 4th Ave, 
#3200 
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

This release was published on openPR.